Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933. The ...

Therefore, the Zacks rating upgrade for Ginkgo Bioworks basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) increased during the last reporting period, rising from 7.37M to 7.83M. This put 23.51% of the company's publicly available shares short.

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...